An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

IgA Nephropathy (IgAN) Clinical Trial

Official title: Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

Status Completed

Clinical Trial Summary

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid .

Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

Clinical Trial Description

To access the efficacy and safety of MMF compared to corticosteroid in in treatment of proliferative IgA Nephropathy(IgAN). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glomerulonephritis, IGA
• IgA Nephropathy (IgAN)
• Kidney Diseases

• NCT number: NCT01269021
• Study type: Interventional
• Source: Nanjing University School of Medicine
• Status: Completed
• Phase: N/A
• Start date: November 2010
• Completion date: April 2014